Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab

BACKGROUND: In order to help in selecting the optimum bone-modifying agent (BMA; zoledronic acid or denosumab), we investigated the impact of the BMA on the renal function of patients with bone metastases. MATERIALS AND METHODS: The present study consisted of 118 patients who were treated with denos...

Full description

Saved in:
Bibliographic Details
Published in:Int J Clin Oncol
Main Authors: Yamasaki, Mutsushi, Yuasa, Takeshi, Uehara, Sho, Fujii, Yasuhisa, Yamamoto, Shinya, Masuda, Hitoshi, Fukui, Iwao, Yonese, Junji
Format: Artigo
Language:Inglês
Published: Springer Japan 2016
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5124438/
https://ncbi.nlm.nih.gov/pubmed/27402103
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-016-1019-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items